Repolarization and Activation Mapping in Ventricular Tachycardia Ablation: the REDEMPTION Study

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Jan 3, 2025

Keywords

ClinConnect Summary

The REDEMPTION Study is a clinical trial aimed at improving a treatment called ventricular tachycardia (VT) ablation, which helps correct fast and irregular heartbeats. This study will explore a new mapping technique that combines two types of heart signal readings—repolarization and depolarization—to guide doctors during the procedure. Researchers hope that this innovative approach will lead to better outcomes for patients undergoing VT ablation, especially when using a specific mapping and ablation device made by Abbott Labs.

To be eligible for this trial, participants should be adults between the ages of 65 and 87 who need a VT ablation procedure and will be treated using a specific mapping system and ablation catheter provided by Abbott Labs. This means that if you are selected, you can expect to undergo routine heart monitoring and receive the latest techniques in VT treatment. It's important to note that this trial is not yet recruiting participants, so it may take some time before individuals can join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ventricular tachycardia ablation procedure;
• • 2. High density endocardial or epicardial substrate EAM performed with the multipolar mapping catheter Advisor™ HD-Grid Mapping Catheter, (Abbott Labs, Abbott Park, IL, USA) in association with the EnsiteXTM Cardiac Mapping System, (Abbott Labs, Abbott Park, IL, USA); 3) Use of TactiFlexTM ablation catheter (Abbott Labs, Abbott Park, IL, USA).
• Exclusion Criteria:
• • 1) use of a different mapping system